From Collaboration to Publication: Salipro® Enables GPCR Antibody Discovery

We're glad that our partnership with Bio-Rad Laboratories is featured in their new publication in mAbs:  “Pioneer: A Synthetic Human Antibody Phage Display Library for Rapid Therapeutic Lead Generation.”

Targeting GPCRs like CXCR4 is a major challenge in antibody discovery. Using our Salipro® platform, we stabilized CXCR4 in its native form, enabling Bio-Rad’s Pioneer™ library to generate a diverse panel of high-affinity, functional antibodies.

Key highlights:

• Exceptional Affinity: 92% of antibodies with <10 nM affinity, with 33% showing sub-nanomolar binding, outperforming the clinical benchmark, ulocuplumab.

• Potent Functionality: Several antibodies demonstrated superior inhibition of cancer cell migration in functional assays.

• Excellent Developability: Five lead candidates with strong biophysical properties were identified, ready for further development.

This synergistic approach was a clear success, leading to the direct identification of multiple high-affinity, functionally active anti-CXCR4 antibodies with excellent developability. The Salipro® platform unlocks access to challenging membrane protein targets, and Bio-Rad's Pioneer™ platform rapidly turns them into high-quality therapeutic candidates. Together, these platforms enable the pursuit of entirely new therapeutic avenues.

Congratulations to all teams and collaborators at Bio-Rad on this achievement and publication! We look forward to seeing how these technologies will continue to accelerate the development of new medicines for patients in need.

Read the full paper here:
M. Putyrski, M.,  et al., Pioneer: a synthetic human antibody phage display library for rapid therapeutic lead generation. mAbs, 17(1) (2025).